Skip to main content
. 2015 Oct 12;6(39):41884–41901. doi: 10.18632/oncotarget.6099

Figure 1. Cav1 expression in human HNSCC tissue specimens.

Figure 1

A. Quantified analysis of CAV1 transcripts determined in 11 primary tumor samples of patients that developed metastasis (“R1”) and 57 primary tumor samples of patients that did not developed metastasis (“non-R1”). The line within the bar represents the mean value and “o” represent individual data point. (***p < 0.001). B. Immunohistochemical analysis of Cav1 in R1 and non-R1 FFPE tissus (original magnification: X100). Table show % of non-R1 and R1 tumors with 0%, 1-25%, 25-75% and >75% Cav1-positive cells. C. Kaplan-Meier analysis of the distant metastasis-free survival (MFS) in patients stratified according Cav1 gene expression (CAV1(+) and CAV1 (−)). A cut-off value was determined for Cav1 gene expression (measured by qRT-PCR), corresponding to a 90.1% sensitivity and a 81.4% specificity with respect to the “R1” status (i.e. 90.1% of the “R1” lesions display a Cav1 expression level below this cut-off, and 81.4% of the “non-R1” tumours express Cav1 levels above this cut-off. More detail in suppl. material and methods). Samples were considered as Cav1-negative is the qRT-PCR value was ≤ to the cut-off. Shorter time to metastasis ***p < 0.001). D. Kaplan-Meier analysis of the overall survival (OS) in patients stratified according Cav1 gene expression (CAV1(+) and CAV1 (−)) as described in Fig 1C. Shorter time to death, **p = 0.003).